The definitive diagnosis and early treatment of many immune-mediated inflammatory
diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic …

Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing
course, affecting up to~ 2–3% of the general adult population worldwide. The interleukin (IL) …

Background The transition from psoriasis (PsO) to psoriatic arthritis (PsA) and the early
diagnosis of PsA is of considerable scientific and clinical interest for the prevention and …

Objective A simple, scalable tool that identifies psoriasis patients at high risk for developing
psoriatic arthritis (PsA) could improve early diagnosis. We aimed to develop a risk prediction …

While the data do not clearly support a single dietary intervention across the disease, weight
loss among those who are obese results in improved PsA disease activity and physical …

Objective To construct a predictive model for Psoriatic Arthritis (PsA) based on clinical and
ultrasonic characteristics in patients with plaque psoriasis (PsP). Patients and Methods …

Objective Evaluate patient‐reported outcomes after 6 months of on‐label guselkumab use in
patients with rheumatologist‐diagnosed active psoriatic arthritis (PsA) enrolled in the …

Background Limited data exist to predict the development of psoriatic arthritis (PsA) in
patients with psoriasis (PsO). Objective To analyze factors associated with incident PsA in …

Psoriatic arthritis (PsA) is a chronic, immunemediated arthritis that presents heterogeneously
with a wide range of symptoms, including joint and enthesis inflammation. 1 Around 1 in 3 …

Objective We analyzed adverse events (AEs) related to adalimumab and etanercept using
the Food and Drug Administration Adverse Event Reporting System (FAERS) to detect …